The DOI matches its Crossref record.
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Abstract
We studied the accumulation of neurofibrillary tangles (NFTs) and senile plaques (SPs) in 10 Alzheimer's disease patients who had been examined during life. We counted NFTs and SPs in 13 cytoarchitectural regions representing limbic, primary sensory, and association cortices, and in subcortical neurotransmitter-specific areas. The degree of neuropathologic change was compared with the severity of dementia, as assessed by the Blessed Dementia Scale and duration of illness. We found that (1) the severity of dementia was positively related to the number of NFTs in neocortex, but not to the degree of SP deposition; (2) NFTs accumulate in a consistent pattern reflecting hierarchic vulnerability of individual cytoarchitectural fields; (3) NFTs appeared in the entorhinal cortex, CA1/subiculum field of the hippocampal formation, and the amygdala early in the disease process; and (4) the degree of SP deposition was also related to a hierarchic vulnerability of certain brain areas to accumulate SPs, but the pattern of SP distribution was different from that of NFT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that their number and location correlates with neuronal loss, disease severity and clinical course [65, 66].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [66]
In the citing paper
“Neurofibrillary tangles and quantitative neuronal loss, but not amyloid plaques, have been found to correlate with disease severity and dementia duration [21–23].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [22]
In the citing paper
“to correlate with measures of cognitive decline (Arriagada et al., 1992) in humans.”
From Network analysis identifies strain-dependent response to tau and tau seeding-associated genes (2023) · cites this paper as Arriagada et al., 1992
In the citing paper
“In AD patients, the clinical severity of dementia strongly correlates with the load of pathological tau aggregates. 3 , 4”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [3]
In the citing paper
“Correlations between NFT density and clinical symptoms, such as a cognitive decline in AD, have been demonstrated [11, 12].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Increasing evidence demonstrates that the cognitive dysfunction and severity of the disease are more related to tau pathology [11–14].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Tau has received increasing attention as a potential therapeutic target, since evidence indicates that tau pathology is more associated with cognitive dysfunction.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“NFTs and quantitative neuronal loss may be more closely correlated with disease severity and dementia progression than the amyloid plaque burden [20–22].”
From Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update (2023) · cites this paper as [21]
In the citing paper
“the best pathological correlate for clinical symptoms to date is the extent of NFT formation (Arriagada et al., 1992; Brier et al., 2016; Giannakopoulos et al., 2003)”
From Selective Neuronal Vulnerability in Alzheimer’s Disease: A Network-Based Analysis (2020) · cites this paper as Arriagada et al., 1992
In the citing paper
“a large number of studies have arrived at a common finding, namely, there is a strong link between neocortical NFTs and cognitive decline (Tomlinson et al., 1970; Duyckaerts et al., 1990, 1997, 1998; Mckee et al., 1991; Arriagada et al., 1992;”
From Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014) · cites this paper as Arriagada et al., 1992
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 601–700 of 1,025
Transgenic mouse models of Alzheimer’s disease
Janus, C., Chishti, M. A., & Westaway, D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00033-8 · Cited by 101
Leoni, V. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.088 · Cited by 102
Immunotherapy for Alzheimer's disease
Wısnıewskı, T., & Goñi, F. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.020 · Cited by 103
Executive Cognitive Impairment: A Novel Perspective on Dementia
Royall, D. R. (2000) · Neuroepidemiology · doi:10.1159/000026268 · Cited by 99
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
“The clinical phenotype and severity in AD is determined principally by the topographic distribution and density of neuronal loss and NFTs, starting in the hippocampal formation and extending into inferior and lateral temporal cortex and beyond (Arriagada et al., 1992; Bancher et al., 1993; Giannakopoulos et al., 1998,…”
BackgroundZhou, S., Yu, G., Chi, L., Zhu, J., Zhang, W., Zhang, Y., & Zhang, L. (2013) · NeuroToxicology · doi:10.1016/j.neuro.2013.07.007 · Cited by 100
Panza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 103
Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects
Knopman, D. S., Lundt, E. S., Therneau, T. M., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., Machulda, M. M., et al. (2019) · Brain · doi:10.1093/brain/awz025 · Cited by 104
Neuronal intermediate filaments and neurodegenerative disorders
Perrot, R., & Eyer, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.06.004 · Cited by 102
Behavior of neural stem cells in the Alzheimer brain
Waldau, B., & Shetty, A. K. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8053-y · Cited by 101
Li, X., & Buxbaum, J. N. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-79 · Cited by 104
Wengenack, T. M., Whelan, S. L., Curran, G. L., Duff, K., & Poduslo, J. F. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00388-2 · Cited by 97
Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type.
Re, T. R., Frank, A., & Hernánz, Á. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.3.280 · Cited by 100
Kurata, T., Miyazaki, K., Kozuki, M., Panin, V.-L., Morimoto, N., Ohta, Y., Nagai, M., Ikeda, Y., Matsuura, T., & Abe, K. (2011) · Brain Research · doi:10.1016/j.brainres.2010.11.067 · Cited by 98
Tau as a Therapeutic Target for Alzheimers Disease
Boutajangout, A., Sigurdsson, E. M., & Krishnamurthy, P. K. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717195 · Cited by 102
Synaptic plasticity in Alzheimer’s disease and healthy aging
Torres, D. M. C., & Cárdenas, F. P. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0058 · Cited by 101
Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies
Zhang, X., Wang, J., Zhang, Z., & Ye, K. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00429-6 · Cited by 119
Role of neurotransmission in the regulation of amyloid β-protein precursor processing
Nitsch, R. M., & Growdon, J. H. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90325-5 · Cited by 99
Self-citationTau‐66: evidence for a novel tau conformation in Alzheimer's disease
Ghoshal, N., García‐Sierra, F., Fu, Y., Beckett, L. A., Mufson, E. J., Kuret, J., Berry, R. W., & Binder, L. I. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00346.x · Cited by 97
Villemagne, V. L., Furumoto, S., Fodero‐Tavoletti, M. T., Harada, R., Mulligan, R. S., Kudo, Y., Masters, C. L., Yanai, K., Cc, R., & Okamura, N. (2012) · Future Neurology · doi:10.2217/fnl.12.34 · Cited by 101
Latimer, C. S., Burke, B. T., Liachko, N. F., Currey, H. N., Kilgore, M. D., Gibbons, L. E., Henriksen, J. C., Darvas, M., Domoto‐Reilly, K., Jayadev, S., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0743-1 · Cited by 102
TRIM11 protects against tauopathies and is down-regulated in Alzheimer’s disease
Zhang, Z., Harischandra, D. S., Wang, R., Ghaisas, S., Zhao, J. Y., McMonagle, T. P., Zhu, G., Lacuarta, K. D., Song, J., Trojanowski, J. Q., et al. (2023) · Science · doi:10.1126/science.add6696 · Cited by 95
White matter imaging changes in subjective and mild cognitive impairment
Selnes, P., Fjell, A. M., Gjerstad, L., Bjørnerud, A., Wallin, A., Due-Tønnessen, P., Grambaite, R., Stenset, V., & Fladby, T. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.001 · Cited by 75
Diagnosis of Alzheimer’s disease: MRI of the hippocampus vs delayed recall
Laakso, M. P., Hallikainen, M., Hänninen, T., Partanen, K. P. L., & Soininen, H. S. (2000) · Neuropsychologia · doi:10.1016/s0028-3932(99)00111-6 · Cited by 99
Central angiotensin II‐induced Alzheimer‐like tau phosphorylation in normal rat brains
Tian, M., Zhu, D., Xie, W., & Shi, J. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.09.004 · Cited by 97
The neuropathological diagnosis of Alzheimer disease
Jellinger, K. A. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_9 · Cited by 97
Progressive transformation of the cytoskeleton associated with normal aging and Alzheimer's disease
Vickers, J. C., Delacourte, A., & Morrison, J. H. (1992) · Brain Research · doi:10.1016/0006-8993(92)91134-z · Cited by 97
Current Status of Clinical Trials on Tau Immunotherapies
Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96
Montgomery, S. L., Mastrangelo, M. A., Habib, D., Narrow, W. C., Knowlden, S. A., Wright, T. W., & Bowers, W. J. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.001 · Cited by 96
In vivo tau imaging: Obstacles and progress
Villemagne, V. L., & Okamura, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.013 · Cited by 100
Whittington, R. A., Bretteville, A., Dickler, M., & Planel, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.03.004 · Cited by 101
Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies
Vogels, T., Leuzy, A., Cicognola, C., Ashton, N. J., Smolek, T., Novák, M., Blennow, K., Zetterberg, H., Hromádka, T., Žilka, N., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.09.019 · Cited by 99
Lin, Y., Fichou, Y., Zeng, Z., Hu, N. Y., & Han, S. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00627 · Cited by 93
Structural Magnetic Resonance Imaging in Established and Prodromal Alzheimer Disease: A Review
Atiya, M., Hyman, B. T., Albert, M., & Killiany, R. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200307000-00010 · Cited by 101
Self-citationSu, J. H., Deng, G., & Cotman, C. W. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0164 · Cited by 97
GSK-3 inhibitors for Alzheimer’s disease
Ávila, J., & Hernández, F. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11.1527 · Cited by 97
Glucose deficit triggers tau pathology and synaptic dysfunction in a tauopathy mouse model
Lauretti, E., Li, J.-G., Meco, A. D., & Praticò, D. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.296 · Cited by 92
Al‐Hilaly, Y. K., Pollack, S. J., Vadukul, D. M., Citossi, F., Rickard, J. E., Simpson, M. C., Storey, J. M. D., Harrington, C. R., Wischik, C. M., & Serpell, L. C. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.09.007 · Cited by 93
Perez, S. E., Raghanti, M. A., Hof, P. R., Kramer, L., Ikonomovic, M. D., Lacor, P. N., Erwin, J. M., Sherwood, C. C., & Mufson, E. J. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23428 · Cited by 95
“Clinical pathological studies have demonstrated that, unlike diffuse plaques, neuritic plaques as well as the amount and distribution of NFT correlate with cognitive decline in AD (Arriagada et al., 1992; Nagy et al., 1995; Gomez-Isla et al., 1996; Giannakopoulos et al., 2003).”
BackgroundCharacteristics and consequences of muscarinic receptor activation by tau protein
Gómez‐Ramos, A., Dı́az-Hernández, M., Rubio, A., Díaz‐Hernandéz, J. I., Miras‐Portugal, M. T., & Ávila, J. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.04.006 · Cited by 95
Tau-mediated synaptic damage in Alzheimer’s disease
Jadhav, S., Cubinkova, V., Zimova, I., Brezováková, V., Maďari, A., Cigánková, V., & Žilka, N. (2015) · Translational Neuroscience · doi:10.1515/tnsci-2015-0023 · Cited by 97
Effects of Alzheimer disease on memory for verbal emotional information
Kensinger, E. A. (2004) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2003.11.011 · Cited by 96
Chin, J., Knowles, R. B., Schneider, A., Drewes, G., Mandelkow, E., & Hyman, B. T. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.11.966 · Cited by 95
Self-citationNeuropathologic Changes of the Temporal Pole in Alzheimer's Disease and Pick's Disease
Arnold, S. E., Hyman, B. T., & Hoesen, G. W. V. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540140051014 · Cited by 93
Self-citationDickstein, D. L., Brautigam, H., Stockton, S. D., Schmeidler, J., & Hof, P. R. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0245-1 · Cited by 99
Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation
Rankin, C. A., Sun, Q., & Gamblin, T. C. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.04.012 · Cited by 95
Adult neurogenesis is functionally associated with AD-like neurodegeneration
Chen, Q., Nakajima, A., Choi, S. H., Xiong, X., Sisodia, S. S., & Tang, Y. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.09.005 · Cited by 94
Tau aggregation into fibrillar polymers: taupathies
Ávila, J. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01676-8 · Cited by 94
Rosenmann, H., Grigoriadis, N., Eldar-Levy, H., Avital, A., Rozenstein‐Tsalkovich, L., Touloumi, O., Behar, L., Ben‐Hur, T., Avraham, Y., Berry, E., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.03.007 · Cited by 93
Temporal Sequence of Alzheimer’s Disease-Related Pathology
Braak, H., & Braak, E. (1999) · Cerebral cortex · doi:10.1007/978-1-4615-4885-0_14 · Cited by 95
Yin, X., Jin, N., Shi, J., Zhang, Y., Wu, Y., Gong, C.-X., Iqbal, K., & Liu, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-00682-y · Cited by 93
Ally, B. A., Gold, C. A., & Budson, A. E. (2008) · Brain and Cognition · doi:10.1016/j.bandc.2008.11.003 · Cited by 99
Lord, A., Englund, H., Söderberg, L., Tucker, S. M., Clausen, F., Hillered, L., Gordon, M. N., Morgan, D., Lannfelt, L., Pettersson, F. E., et al. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06836.x · Cited by 92
MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD
Desikan, R. S., Fischl, B. R., Cabral, H., Kemper, T. L., Guttmann, C. R. G., Blacker, D., Hyman, B. T., Albert, M., & Killiany, R. (2008) · Neurology · doi:10.1212/01.wnl.0000320055.57329.34 · Cited by 93
Self-citationRelational Integration and Executive Function in Alzheimer's Disease.
Waltz, J. A., Knowlton, B. J., Holyoak, K. J., Boone, K. B., Back‐Madruga, C., McPherson, S. E., Masterman, D. L., Chow, T. W., Cummings, J. L., & Miller, B. L. (2004) · Neuropsychology · doi:10.1037/0894-4105.18.2.296 · Cited by 97
Garrido, G. E. J. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.5.508 · Cited by 91
BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1531706 · Cited by 92
Murugan, N. A., Nordberg, A., & Ågren, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00093 · Cited by 92
Zhang, W., Hao, J., Liu, R., Zhang, Z., Lei, G., Su, C., Miao, J., & Li, Z. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.03.072 · Cited by 100
Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults
Meyer, P., Ashton, N. J., Karikari, T. K., Strikwerda‐Brown, C., Köbe, T., Gonneaud, J., Binette, A. P., Ozlen, H., Yakoub, Y., Simrén, J., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26308 · Cited by 95
Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., & Gong, C. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130491 · Cited by 92
Hyman, B. T., Elvhage, T. E., & Reiter, J. S. (1994) · PubMed Central · Cited by 92
Self-citationWang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Litvinchuk, A., Huynh, T. V., Shi, Y., Jackson, R. J., Finn, M. B., Manis, M., Francis, C. M., Tran, A. C., Sullivan, P. M., Ulrich, J. D., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26043 · Cited by 91
Self-citationEdrey, Y. H., Medina, D. X., Gaczynska, M. E., Osmulski, P. A., Oddo, S., Caccamo, A., & Buffenstein, R. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.032 · Cited by 95
Binetti, G. G., Locascio, J. J., Corkin, S., Vonsattel, J. P., & Growdon, J. H. (2000) · Archives of Neurology · doi:10.1001/archneur.57.2.225 · Cited by 89
Self-citationDai, C., Chen, X., Kazim, S. F., Liu, F., Gong, C., Grundke, I., & Iqbal, K. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1315-y · Cited by 94
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Structural networks in Alzheimer's disease
Reid, A., & Evans, A. C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.11.010 · Cited by 94
A Systematic Review of MicroRNA Expression as Biomarker of Late-Onset Alzheimer’s Disease
Herrera-Espejo, S., Santos-Zorrozua, B., Álvarez-González, P., Lopez-Lopez, E., & Garcia-Orad, Á. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01676-9 · Cited by 81
Nerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease
Mufson, E. J., Counts, S., Ginsberg, S. D., Mahady, L. J., Perez, S. E., Massa, S. M., Longo, F. M., & Ikonomović, M. D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00533 · Cited by 94
The morbid anatomy of dementia in Parkinson’s disease
Kalaitzakis, M. E., & Pearce, R. K. B. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0597-x · Cited by 90
Sahara, N., Maeda, S., Yoshiike, Y., Mizoroki, T., Yamashita, S., Murayama, M., Park, J. ‐., Saito, Y., Murayama, S., & Takashima, A. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21417 · Cited by 90
Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., & Hu, S. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000129 · Cited by 90
Capsaicin reduces Alzheimer-associated tau changes in the hippocampus of type 2 diabetes rats
Xu, W., Liu, J., Ma, D., Yuan, G., Lü, Y., & Yang, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172477 · Cited by 89
Papasozomenos, S. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6612 · Cited by 89
Correlation Between Aβx-40–, Aβx-42–, and Aβx-43–Containing Amyloid Plaques and Cognitive Decline
Parvathy, S., Davies, P., Haroutunian, V. H., Purohit, D. P., Davis, K. L., Mohs, R. C., Park, H., Moran, T. M., Chan, J. Y., & Buxbaum, J. D. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.2025 · Cited by 90
The diffeomorphometry of temporal lobe structures in preclinical Alzheimer's disease
Miller, M. I., Younes, L., Ratnanather, J. T., Brown, T., Trinh, H., Postell, E., Lee, D. S., Wang, M.-C., Mori, S., O'Brien, R., et al. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.09.001 · Cited by 88
Targeting Tau Protein in Alzheimerʼs Disease
Gong, C., Grundke, I., & Iqbal, K. (2010) · Drugs & Aging · doi:10.2165/11536110-000000000-00000 · Cited by 90
Chhimpa, N., Singh, N., Puri, N., & Kayath, H. P. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220514 · Cited by 89
The Unfolded Protein Response Protects from Tau Neurotoxicity In Vivo
Loewen, C. A., & Feany, M. Β. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013084 · Cited by 92
Muramori, F., Kobayashi, K., & Nakamura, I. (1998) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1998.tb02706.x · Cited by 86
Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease
Driver, J. A., Zhou, X. Z., & Lu, K. P. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.12.025 · Cited by 95
Shin, R., Kruck, T. P. A., Murayama, H., & Kitamoto, T. (2003) · Brain Research · doi:10.1016/s0006-8993(02)03893-3 · Cited by 88
Emerging Therapeutics for Alzheimer's Disease
Chiang, K., & Koo, E. H. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135932 · Cited by 95
Tapias, V., Jainuddin, S., Ahuja, M., Stack, C., Elipenahli, C., Vignisse, J., Gerges, M., Starkova, N. N., Xu, H., Starkov, A. A., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy201 · Cited by 91
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies
Wagner, J., Krauß, S., Shi, S., Ryazanov, S., Steffen, J., Miklitz, C., Leonov, A., Kleinknecht, A., Göricke, B., Weishaupt, J. H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1483-3 · Cited by 87
Approach to atypical Alzheimer’s disease and case studies of the major subtypes
Dickerson, B. C., McGinnis, S. M., Xia, C., Price, B. H., Atri, A., Murray, M. E., Mendez, M. F., & Wolk, D. A. (2017) · CNS Spectrums · doi:10.1017/s109285291600047x · Cited by 86
The association between tau PET and retrospective cortical thinning in clinically normal elderly
LaPoint, M. R., Chhatwal, J. P., Sepulcre, J., Johnson, K. A., Sperling, R. A., & Schultz, A. P. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.049 · Cited by 84
Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 92
Copper (II) modulates in vitro aggregation of a tau peptide
Zhou, L., Du, J., Zeng, Z., Wu, W., Zhao, Y., Kanazawa, K., Ishizuka, Y., Nemoto, T., Nakanishi, H., & Li, Y. (2007) · Peptides · doi:10.1016/j.peptides.2007.08.022 · Cited by 87
Kurz, A., Egensperger, R., Haupt, M., Lautenschlager, N. T., Romero, B., Graeber, M. B., & Müller, U. (1996) · Neurology · doi:10.1212/wnl.47.2.440 · Cited by 87
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., & Rosenmann, H. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819ac3cb · Cited by 86
The role of glycogen synthase kinase 3 in the early stages of Alzheimers’ disease
Hernández, F., & Ávila, J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.026 · Cited by 88
Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy
Mazzaro, N., Barini, E., Spillantini, M. G., Goedert, M., Medini, P., & Gasparini, L. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0774-15.2016 · Cited by 87
C99 selectively accumulates in vulnerable neurons in Alzheimer's disease
Pulina, M. V., Hopkins, M., Haroutunian, V. H., Greengard, P., & Bustos, V. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.09.002 · Cited by 90
Dendritic Spines: Mediators of Cognitive Resilience in Aging and Alzheimer’s Disease
Walker, C. K., & Herskowitz, J. H. (2021) · The Neuroscientist · doi:10.1177/1073858420945964 · Cited by 86
Accepting its Random Coil Nature Allows a Partial NMR Assignment of the Neuronal Tau Protein
Smet‐Nocca, C., Leroy, A., Sillen, A., Wieruszeski, J., Landrieu, I., & Lippens, G. M. (2004) · ChemBioChem · doi:10.1002/cbic.200400145 · Cited by 95
Cerebral Hypoperfusion, Capillary Degeneration, and Development of Alzheimer Disease
de la Torre, J. C. (2000) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200000001-00012 · Cited by 86
Neurodegeneration in an Aβ‐induced model of Alzheimer’s disease: the role of Cdk5
Lopes, J. P., Oliveira, C. R., & Agostinho, P. M. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00536.x · Cited by 96
Metadata
- Authors
- Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- ORCID
- Hyman, Bradley T.
- Venue
- Neurology
- Published
- 1992-03
- Volume
- 42
- Issue
- 3
- Pages
- 631-631
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2053116497
- Cited by
- 2,668
- References
- 0
- Citations by year
- 2026: 54 · 2025: 89 · 2024: 81 · 2023: 101 · 2022: 89 · 2021: 141 · 2020: 135 · 2019: 131 · 2018: 96 · 2017: 112 · 2016: 132 · 2015: 101 · 2014: 106 · 2013: 93 · 2012: 97
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-08487, P50 AG05134, P50AG005134)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary tangles, amyloid plaques, dementia severity, disease duration, neuropathology, entorhinal cortex, hippocampal formation, amygdala, regional vulnerability, cytoarchitecture
- MeSH terms
- Aged, Alzheimer Disease, Amygdala, Brain, Female, Hippocampus, Humans, Male, Middle Aged, Neurofibrillary Tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
